Abstract

BackgroundPlasmodium falciparum dihydrofolate reductase-thymidylate synthase (pfDHFR-TS) is a well-defined target of anti-malarial drug, such as pyrimethamine and cycloguanil. Emergence of malaria parasites resistant to these drugs has been shown to be associated with point mutations of the gene coding for the target enzymes. Although the 3D-structure of P. falciparum bifunctional pfDHFR-TS has been reported previously, relatively little is known about the interactions between the pfDHFR and pfTS domains and the roles of the junctional region that links the two domains together. Therefore, a thorough understanding of the interaction of the two domains and the role of the junctional region of this target is important as the knowledge could assist the development of new effective anti-malarial drugs aimed at overcoming drug-resistant malaria.MethodsA system was developed to investigate the interaction between pfDHFR and pfTS domains and the role of the junctional region on the activity of the recombinant pfTS. Based on the ability of co-transformed plasmids coding for pfDHFR and pfTS with truncated junctional region to complement the growth of TS-deficient Escherichia coli strain χ2913recA(DE3) on minimum media without thymidine supplementation, active pfTS mutants with minimal length of junctional region were identified. Interactions between active pfDHFR and the pfTS domains were demonstrated by using a bacterial two-hybrid system.ResultsUsing TS-deficient E. coli strain χ2913recA(DE3), the authors have shown for the first time that in P. falciparum a junctional region of at least 44 amino acids or longer was necessary for the pfTS domain to be active for the synthesis of thymidylate for the cells. Truncation of the junctional region of the bifunctional pfDHFR-TS further confirmed the above results, and suggested that a critical length of the junctional peptide of pfDHFR-TS would be essential for the activity of TS to catalyze the synthesis of thymidylate.ConclusionThe present study demonstrated the interactions between the pfDHFR and pfTS domains of the bifunctional pfDHFR-TS, and revealed that the junctional region linking the two protein domains is essential for the expression of catalytically active pfTS domain. The findings could be useful since inhibition of the pfDHFR-TS domain-domain interaction could form a basis for the development of new anti-malarial drugs based on targeting the non-active site region of this important enzyme.

Highlights

  • Plasmodium falciparum dihydrofolate reductase-thymidylate synthase is a well-defined target of anti-malarial drug, such as pyrimethamine and cycloguanil

  • Evidence from deletion of pfDHFR-TS suggested that the amino terminus of the pfDHFR domain is important for the function of the pfTS domain, and interactions between the pfDHFR and pfTS domains are important [18]

  • Results from growth complementation monitored after incubation of the plates overnight at 37°C revealed that pET-pfJRTS△232-235, pET-pfJRTS△232-251, pET-pfJRTS△232-265, pET-pfJRTS△ 232-271, pET-pfJRTS△232-274, and pET-pfJRTS△232276 with corresponding junctional region (JR) length of 85, 69, 55, 49, 46, 44 amino acid residues, respectively, could grow on minimum media (Figure 4A, lanes 2–7), while pETpfJRTS△232-277 and pET-pfJRTS△232-299 which had the JR length of 43 and 21 residues, respectively, did not show growth complementation (Figure 4A, lanes 8–9)

Read more

Summary

Introduction

Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (pfDHFR-TS) is a well-defined target of anti-malarial drug, such as pyrimethamine and cycloguanil. A thorough understanding of the interaction of the two domains and the role of the junctional region of this target is important as the knowledge could assist the development of new effective anti-malarial drugs aimed at overcoming drug-resistant malaria. Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (pfDHFR-TS) is a well-defined target of antifolate drugs such as pyrimethamine and cycloquanil. The emergence of anti-folate resistance has compromised the utility of the drugs and presented an urgent need to discover new drug targets and to develop novel effective drugs to combat drug-resistant parasites

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call